Our Story

Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.

After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device industry’s first successful large-scale Level l, randomized sham-controlled trial for chronic vertebrogenic low back pain. Relievant is now sponsoring the INTRACEPT Study — a Level l, prospective, randomized clinical study comparing the Intracept Procedure to non-surgical management for patients with chronic vertebrogenic low back pain.

The INTRACEPT Study was initiated in September 2017 and concluded enrollment in January 2019 due to the highly significant treatment effect of the Intracept Procedure compared to non-surgical management.

In 2018, Relievant initiated the US market release of the Intracept Procedure, announced the successful completion of the first commercial Intracept Procedures, and received 510(k) Clearance for the commercial Intracept System.

  • 2006

    October: Relievant Founded

  • 2008

    September: CE Mark Approval

  • 2010

    June: Pilot Study Completed

  • 2015

    February: SMART Trial Completed

  • 2016

    July: FDA 510(k) Clearance

  • 2018

    February: SMART Trial Publication – 12 Month Results

    July: First Commercial Intracept Procedures

    September: FDA 510(k) Clearance for Commercial Intracept System

  • 2019

    April: SMART Trial Publication – 24 Month Results